Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 6/2011

01-12-2011 | Mediators, Mechanisms in Tissue Injury (Heinrich Taegtmeyer, Steven A. Atlas, Section Editors)

Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity

Authors: Rajesh Gupta, Michael L. Maitland

Published in: Current Hypertension Reports | Issue 6/2011

Login to get access

Abstract

Kinase inhibitors have emerged as an important new class of agents for the treatment of diverse tumors. Sunitinib malate is a small-molecule, oral, multi-kinase inhibitor approved for use in treating renal cell carcinoma and gastrointestinal stromal tumor. It has also demonstrated efficacy in treating pancreatic neuroendocrine tumors and is being evaluated for the treatment of other cancers. Initially developed for its inhibition of the vascular endothelial growth factor (VEGF) signaling pathway, sunitinib has been associated with hypertension and heart failure. This review examines the incidence and severity of these adverse events, relevant findings from other agents that inhibit VEGF signaling, the mechanisms underlying these effects, and suggestions for their clinical management. Hypertension is a common adverse effect that is usually easily managed. The associated heart failure is less common; it can be reversible but must be actively monitored and managed. Mechanistic insights suggest that an attentive clinical strategy for hypertension could prevent severe cardiotoxicity.
Literature
1.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med. 2007;356(2):115–24.PubMedCrossRef
2.
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.PubMedCrossRef
3.
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med. 2011;364(6):501–13.PubMedCrossRef
4.
Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9.PubMedCrossRef
5.
Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009;23(1):97–107. viii-ix.PubMedCrossRef
6.
Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Canc. 2009;9(1):28–39.CrossRef
7.
Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106(1):21–34.PubMedCrossRef
8.
Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10(2):111–26.PubMedCrossRef
9.
Rees ML, Khakoo AY. Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies. Heart Fail Clin. 2011;7(3):299–311.PubMedCrossRef
10.
Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9–17.PubMedCrossRef
11.
Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Canc Inst. 2011;103(9):763–73.CrossRef
12.
Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Canc Res. 2009;15(19):6250–7.CrossRef
13.
•• Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. New Engl J Med. 2008;358(1):95–7. This study demonstrated the potential for blood pressure as a pharmacodynamic marker of sunitinib. It was the first study to clearly demonstrate the return of blood pressure to baseline levels with sunitinib withdrawal. PubMedCrossRef
14.
Facemire CS, Nixon AB, Griffiths R, et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652–8.PubMedCrossRef
15.
Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 2010;56(6):1131–6.PubMedCrossRef
16.
• Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927–34. This study demonstrated that capillary rarefaction occurs in human patients after prolonged treatment with a regimen containing bevacizumab. PubMedCrossRef
17.
Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290(2):H560–76.PubMedCrossRef
18.
Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12.PubMedCrossRef
19.
Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29(6):632–8.PubMedCrossRef
20.
McArthur HL, Rugo H, Nulsen B, et al. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Canc Res. 2011;17(10):3398–407.CrossRef
21.
•• Chintalgattu V, Ai D, Langley RR, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Investig. 2010;120(2):472–84. This mechanistic study demonstrated the importance of PDGF signaling in cardiac response to afterload stress and forms the basis for the “two-hit” hypothesis of KI-associated cardiac toxicity. PubMedCrossRef
22.
Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127–32.PubMedCrossRef
23.
Ghoreschi K, Laurence A, O’Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol. 2009;10(4):356–60.PubMedCrossRef
24.
Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009;2(1):15–25.PubMedCrossRef
25.
•• Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Canc Inst. 2010;102(9):596–604. This article provides a more comprehensive rationale for blood pressure control in patients receiving VEGF signaling pathway inhibitors. CrossRef
26.
Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27(36):6152–9.PubMedCrossRef
27.
• Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010;28(6):949–54. Many prior publications reported an association between hypertension and therapeutic effects of VEGF signaling inhibitors. This analysis relied on intravenously administered bevacizumab and an optimal “landmark analysis” interrogation and should be recognized as the first to demonstrate convincingly an association between blood pressure elevations and improved outcomes with this class of anticancer agents. PubMedCrossRef
28.
Curwen JO, Musgrove HL, Kendrew J, et al. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Canc Res. 2008;14(10):3124–31.CrossRef
29.
Franklin PH, Banfor PN, Tapang P, et al. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther. 2009;329(3):928–37.PubMedCrossRef
30.
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 2007;356(2):125–34.PubMedCrossRef
31.
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.PubMedCrossRef
32.
Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR$20. J Clin Oncol. 2007;25(27):4278–84.PubMedCrossRef
Metadata
Title
Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity
Authors
Rajesh Gupta
Michael L. Maitland
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 6/2011
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-011-0229-4

Other articles of this Issue 6/2011

Current Hypertension Reports 6/2011 Go to the issue

Special Situations in the Management of Hypertension (Theodore Kotchen, Section Editor)

Does Sustained Weight Loss Reverse the Metabolic Syndrome?

Special Situations in the Management of Hypertension (Theodore Kotchen, Section Editor)

Immune Mechanisms in Hypertension

Mediators, Mechanisms, and Pathways in Tissue Injury (Heinrich Taegtmeyer and Steven Atlas, Section Editors)

Effects of Relaxin on Arterial Dilation, Remodeling, and Mechanical Properties

Mediators, Mechanisms in Tissue Injury (Heinrich Taegtmeyer, Steven Atlas, Section Editors)

The Roles of Integrins in Mediating the Effects of Mechanical Force and Growth Factors on Blood Vessels in Hypertension

Literature Alert

Something New to Offer: Renal Denervation

Invited Commentary

Improvement of Sodium Status to Optimize the Efficacy of Renin-Angiotensin System Blockade

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits